High-content Image-based Drug Testing of Patients’ Primary Fibroblasts Reveals Potential New Treatment Options for Localized Scleroderma
DOI:
https://doi.org/10.2340/actadv.v105.43088Keywords:
Localized scleroderma, Myofibroblasts, transforming growth factor beta, antifibrotic agents, high throughput screening assayAbstract
Localized scleroderma is a rare autoimmune disease characterized by progressive fibrosis of the skin and its underlying structures, causing loss of normal tissue structure and function. Myofibroblasts, differentiated from fibroblasts by high expression of α-smooth muscle actin, play a key role in the pathogenesis with continuous production of collagen and other extracellular matrix components. Transforming growth factor β promotes myofibroblast transformation and is central to the pathogenesis of fibrotic diseases. Targeted therapies for skin fibrosis are lacking, and current treatment consisting of topical steroids and immunosuppressive drugs often has limited efficacy. In this study, testing was performed with 78 drugs on lesional localized scleroderma fibroblasts to find potential new therapies, with α-smooth muscle actin and collagen-1 expression as markers for antifibrotic effect. Several drugs belonging to inhibitors of tyrosine kinase, phosphoinositide-3 kinase, and transforming growth factor β receptor were found to have an antifibrotic effect in localized scleroderma fibroblasts. Along with increased expression of transforming growth factor β1, Smad3, and AKT found in lesional localized scleroderma skin, these results confirm transforming growth factor β pathway as a treatment target. Additionally, androgen receptor antagonists showed potential antifibrotic effects, co-aligning with an increased expression of androgen receptor in localized scleroderma skin.
Downloads
References
Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64: 217–228; quiz 229–230. DOI: https://doi.org/10.1016/j.jaad.2010.05.045
Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis 2021; 9: 1101–1145. DOI: https://doi.org/10.1002/iid3.475
Kreuter A. Localized scleroderma. Dermatol Ther 2012; 25: 135–147. DOI: https://doi.org/10.1111/j.1529-8019.2012.01479.x
Saracino AM, Denton CP, Orteu CH. The molecular pathogenesis of morphoea: from genetics to future treatment targets. Br J Dermatol 2017; 177: 34–46. DOI: https://doi.org/10.1111/bjd.15001
Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013; 15: 215. DOI: https://doi.org/10.1186/ar4230
Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007; 9: 136–143. DOI: https://doi.org/10.1007/s11926-007-0008-z
van Caam A, Vonk M, van den Hoogen F, van Lent P, van der Kraan P. Unraveling SSc pathophysiology; the myofibroblast. Front Immunol 2018; 9: 2452. DOI: https://doi.org/10.3389/fimmu.2018.02452
Schulz JN, Plomann M, Sengle G, Gullberg D, Krieg T, Eckes B. New developments on skin fibrosis: essential signals emanating from the extracellular matrix for the control of myofibroblasts. Matrix Biol 2018; 68–69: 522–532. DOI: https://doi.org/10.1016/j.matbio.2018.01.025
Frangogiannis N. Transforming growth factor-beta in tissue fibrosis. J Exp Med 2020; 217: e20190103. DOI: https://doi.org/10.1084/jem.20190103
Knobler R, Geroldinger-Simic M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, et al. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 2024; 38: 1251–1280. DOI: https://doi.org/10.1111/jdv.19912
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020; 16: 145–154. DOI: https://doi.org/10.1038/s41584-020-0373-9
Bukiri H, Volkmann ER. Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 2022; 64: 102211. DOI: https://doi.org/10.1016/j.coph.2022.102211
Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature 2020; 587: 555–566. DOI: https://doi.org/10.1038/s41586-020-2938-9
Blay V, Tolani B, Ho SP, Arkin MR. High-throughput screening: today’s biochemical and cell-based approaches. Drug Discov Today 2020; 25: 1807–1821. DOI: https://doi.org/10.1016/j.drudis.2020.07.024
Khedoe P, Marges E, Hiemstra P, Ninaber M, Geelhoed M. Interstitial lung disease in patients with systemic sclerosis: toward personalized-medicine-based prediction and drug screening models of systemic sclerosis-related interstitial lung disease (SSc-ILD). Front Immunol 2020; 11: 1990. DOI: https://doi.org/10.3389/fimmu.2020.01990
Komura K, Yanaba K, Bouaziz JD, Yoshizaki A, Hasegawa M, Varga J, et al. Perspective to precision medicine in scleroderma. Front Immunol 2023; 14: 1298665. DOI: https://doi.org/10.3389/fimmu.2023.1298665
Kim Y, Nam Y, Rim YA, Ju JH. Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis. Stem Cell Res Ther 2022; 13: 303. DOI: https://doi.org/10.1186/s13287-022-02987-w
Roy T, Boateng ST, Uddin MB, Banang-Mbeumi S, Yadav RK, Bock CR, et al. The PI3K-Akt-mTOR and associated signaling pathways as molecular drivers of immune-mediated inflammatory skin diseases: update on therapeutic strategy using natural and synthetic compounds. Cells 2023; 12: 1671. DOI: https://doi.org/10.3390/cells12121671
Qian Y, Peng K, Qiu C, Skibba M, Huang Y, Xu Z, et al. Novel epidermal growth factor receptor inhibitor attenuates angiotensin II-induced kidney fibrosis. J Pharmacol Exp Ther 2016; 356: 32–42. DOI: https://doi.org/10.1124/jpet.115.228080
Wei X, Han J, Chen ZZ, Qi BW, Wang GC, Ma YH, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun 2010; 397: 311–317. DOI: https://doi.org/10.1016/j.bbrc.2010.05.109
Russo RC, Garcia CC, Barcelos LS, Rachid MA, Guabiraba R, Roffe E, et al. Phosphoinositide 3-kinase gamma plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice. J Leukoc Biol 2011; 89: 269–282. DOI: https://doi.org/10.1189/jlb.0610346
Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res 2019; 20: 205. DOI: https://doi.org/10.1186/s12931-019-1161-4
Jun JB, Kuechle M, Min J, Shim SC, Kim G, Montenegro V, et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005; 124: 298–303. DOI: https://doi.org/10.1111/j.0022-202X.2004.23559.x
Suwanabol PA, Seedial SM, Zhang F, Shi X, Si Y, Liu B, et al. TGF-beta and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2012; 302: H2211–2219. DOI: https://doi.org/10.1152/ajpheart.00966.2011
Park SA, Kim MJ, Park SY, Kim JS, Lee SJ, Woo HA, et al. EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-beta/Smad and ROS signaling. Cell Mol Life Sci 2015; 72: 2023–2039. DOI: https://doi.org/10.1007/s00018-014-1798-6
Kim MJ, Park SA, Kim CH, Park SY, Kim JS, Kim DK, et al. TGF-beta type I receptor kinase inhibitor EW-7197 -suppresses cholestatic liver fibrosis by inhibiting HIF1alpha-induced epithelial mesenchymal transition. Cell Physiol Biochem 2016; 38: 571–588. DOI: https://doi.org/10.1159/000438651
Binabaj MM, Asgharzadeh F, Avan A, Rahmani F, Soleimani A, Parizadeh MR, et al. EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation. J Cell Physiol 2019; 234: 11654–11661. DOI: https://doi.org/10.1002/jcp.27823
Yoon SH, Kim KY, Wang Z, Park JH, Bae SM, Kim SY, et al. EW-7197, a transforming growth factor-beta type I receptor kinase inhibitor, ameliorates acquired lymphedema in a mouse tail model. Lymphat Res Biol 2020; 18: 433–438. DOI: https://doi.org/10.1089/lrb.2018.0070
Soleimani A, Asgharzadeh F, Rahmani F, Avan A, Mehraban S, Fakhraei M, et al. Novel oral transforming growth factor-beta signaling inhibitor potently inhibits postsurgical adhesion band formation. J Cell Physiol 2020; 235: 1349–1357. DOI: https://doi.org/10.1002/jcp.29053
Peterson JM, Jay JW, Wang Y, Joglar AA, Prasai A, Palackic A, et al. Galunisertib exerts antifibrotic effects on TGF-beta-induced fibroproliferative dermal fibroblasts. Int J Mol Sci 2022; 23: 6689. DOI: https://doi.org/10.3390/ijms23126689
Zanin-Zhorov A, Blazar BR. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol 2021; 230: 108823. DOI: https://doi.org/10.1016/j.clim.2021.108823
Wang Y, Ma W, Lu S, Yan L, Hu F, Wang Z, et al. Androgen receptor regulates cardiac fibrosis in mice with experimental autoimmune myocarditis by increasing microRNA-125b expression. Biochem Biophys Res Commun 2018; 506: 130–136. DOI: https://doi.org/10.1016/j.bbrc.2018.09.092
Wang D, Zhu Z, Fu Y, Zhang Q, Zhang Y, Wang T, et al. Bromodomain-containing protein 4 activates androgen receptor transcription and promotes ovarian fibrosis in PCOS. Cell Rep 2023; 42: 113090. DOI: https://doi.org/10.1016/j.celrep.2023.113090
Ceruti JM, Leiros GJ, Balana ME. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol 2018; 465: 122–133. DOI: https://doi.org/10.1016/j.mce.2017.09.009
Markova MS, Zeskand J, McEntee B, Rothstein J, Jimenez SA, Siracusa LD. A role for the androgen receptor in collagen content of the skin. J Invest Dermatol 2004; 123: 1052–1056. DOI: https://doi.org/10.1111/j.0022-202X.2004.23494.x
McGaugh S, Kallis P, De Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review. Dermatol Ther 2022; 35: e15437. DOI: https://doi.org/10.1111/dth.15437
Thomas RM, Worswick S, Aleshin M. Retinoic acid for -treatment of systemic sclerosis and morphea: a literature review. Dermatol Ther 2017; 30. DOI: https://doi.org/10.1111/dth.12455
Watanabe H, Bi J, Murata R, Fujimura R, Nishida K, Imafuku T, et al. A synthetic retinoic acid receptor agonist Am80 ameliorates renal fibrosis via inducing the production of alpha-1-acid glycoprotein. Sci Rep 2020; 10: 11424. DOI: https://doi.org/10.1038/s41598-020-68337-z
Leem AY, Shin MH, Douglas IS, Song JH, Chung KS, Kim EY, et al. All-trans retinoic acid attenuates bleomycin-induced pulmonary fibrosis via downregulating EphA2-EphrinA1 signaling. Biochem Biophys Res Commun 2017; 491: 721–726. DOI: https://doi.org/10.1016/j.bbrc.2017.07.122
Lin XY, Chu Y, Zhang GS, Zhang HL, Kang K, Wu MX, et al. Retinoid X receptor agonists alleviate fibroblast activation and post-infarction cardiac remodeling via inhibition of TGF-beta1/Smad pathway. Life Sci 2023; 329: 121936. DOI: https://doi.org/10.1016/j.lfs.2023.121936
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Katariina Mähönen, Isabel Mogollon, Antti Hassinen, Minttu Polso, Katja Välimäki, Swapnil Potdar, Al-Amin Chowdhury, Annamari Ranki, Jani Saarela, Vilja Pietiäinen, Jaana Panelius
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
